secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2026-06-17T20:01:15+00:00
Accession:  0001213900-26-069611
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio stockholders approve Third Amended 2021 Stock Incentive Plan, increasing share reserve to ~9.16M shares
--------------------------------------------------------------------------------

- Stockholders approved Third Amended 2021 Stock Incentive Plan, increasing share reserve from 6.5M to 9,158,525 shares.
- Plan includes evergreen provision: annual auto-increase on first trading day of 2027-2031, up to 10% of outstanding shares.
- All five director nominees elected: David Moss, J. Kelly Ganjei, Tim Schroeder, Scott Juda, Marcia Allen.
- Ratification of CBIZ CPAs P.C. as independent auditor for FY2026 approved with 17,293,255 votes for.
- Broker non-votes: 8,501,317 shares on director elections and plan vote.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390026069611/0001213900-26-069611-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390026069611/ea0295129-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-069611

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer